Complex I, iron, and ferritin in Parkinson's disease substantia nigra
Abstract
Elevated iron levels, enhanced oxidative damage, and complex I deficiency have been identified in the substantia nigra of Parkinson's disease patients. To understand the interrelationship of these abnormalities, we analyzed iron levels, ferritin levels, and complex I activity in the substantia nigra of patients with Parkinson's disease. Total iron levels were increased significantly, ferritin levels were unchanged, and complex I activities were decreased significantly in the substantia nigra samples. The failure of ferritin levels to increase with elevated iron concentrations suggests that the amount of reactive iron may increase in the substantia nigra of Parkinson's disease patients. There was no correlation between the iron levels and complex I activity or the iron-ferritin ratio and complex I activity in the substantia nigra samples.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Increases of iron and a decrease of ferritin in the substantia nigra are indicative of high iron loading of ferritin.
“Increases of iron and a decrease of ferritin in the substantia nigra101,116–119 are indicative of high iron loading of ferritin.120”
From The role of iron in brain ageing and neurodegenerative disorders (2014) · cites this paper as [118]
Cites
Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease
Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Agid, Y., Lees, A. J., Jenner, P. G., & MARSDEN, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09133.x · Cited by 1,397 · see citing works
Self-citationTransition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383 · see citing works
DEXTER, D. T., CARAYON, A., JAVOY-AGID, F., AGID, Y., WELLS, F. R., DANIEL, S. E., LEES, A. J., JENNER, P., & MARSDEN, C. D. (1991) · Brain · doi:10.1093/brain/114.4.1953 · Cited by 1,043 · cited 1× · see citing works
“Also Dexter and coworkers [6] observed increased iron levels and concomitant rises in ferritin concentration in the substantia nigra of patients who had died from either multiplesystem atrophy or progressive supranuclear palsy.”
BackgroundSelf-citationIncreased nigral iron content in postmortem parkinsonian brain
Dexter, D. T., Wells, F. R., Agid, F., Agid, Y., Lees, A. J., Jenner, P., & Marsden, C. D. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91361-4 · Cited by 963 · see citing works
Self-citationSchapira, A. H. V., Mann, V. M., Cooper, J. A. D., Dexter, D. T., Daniel, S. E., Jenner, P. G., Clark, J. B., & MARSDEN, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb05809.x · Cited by 673 · see citing works
Self-citationA Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra
Saggu, H. K., Cooksey, J., Dexter, D. T., Wells, F. R., Lees, A. J., Jenner, P. G., & MARSDEN, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb11759.x · Cited by 454 · see citing works
Self-citationTranslational regulation via iron‐responsive elements by the nitric oxide/NO‐synthase pathway.
Weiss, G., Goossen, B., Doppler, W., Fuchs, D., Pantopoulos, K., Werner‐Felmayer, G., Wachter, H., & Hentze, M. W. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06039.x · Cited by 389 · see citing works
BRAIN, SKELETAL MUSCLE AND PLATELET HOMOGENATE MITOCHONDRIAL FUNCTION IN PARKINSON'S DISEASE
MANN, V. M., COOPER, J. M., KRIGE, D., DANIEL, S. E., SCHAPIRA, A. H. V., & MARSDEN, C. D. (1992) · Brain · doi:10.1093/brain/115.2.333 · Cited by 346 · cited 2× · see citing works
“The finding of a highly statistically significant 32 to 38% decrease in complex I activity in PD presented here extends our previous observations in this area [3].”
BackgroundResultSelf-citationThe possible role of iron in the etiopathology of parkinson's disease
Youdim, M. B. H., Ben‐Shachar, D., & Riederer, P. F. (1993) · Movement Disorders · doi:10.1002/mds.870080102 · Cited by 301 · see citing works
Dexter, D. T., Jenner, P. G., Schapira, A. H. V., & MARSDEN, C. D. (1992) · Annals of Neurology · doi:10.1002/ana.410320716 · Cited by 292 · see citing works
Self-citationDecreased ferritin levels in brain in Parkinson's disease
Dexter, D. T., Carayon, A., Vidailhet, M., Ruberg, M., Agid, F., Agid, Y., Lees, A. J., Wells, F. R., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb08814.x · Cited by 258 · see citing works
Self-citationDedman, D., Treffry, A., Candy, J., Taylor, G. A., Morris, C. M., Bloxham, C. A., Perry, R. H., Edwardson, J. A., & Harrison, P. M. (1992) · Biochemical Journal · doi:10.1042/bj2870509 · Cited by 121 · see citing works
Harford, J. B., & Klausner, R. D. (2017) · Enzyme · doi:10.1159/000468745 · Cited by 87 · see citing works
Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease
Hartley, A., Cooper, J. M., & Schapira, A. H. V. (1993) · Brain Research · doi:10.1016/0006-8993(93)90341-j · Cited by 75 · see citing works
Self-citationα‐tocopherol levels in brain are not altered in Parkinson's disease
Dexter, D. T., Jenner, P. G., Ward, R. J., Peter, T. J., Wells, F. R., Daniel, S. E., Lees, A. J., & MARSDEN, C. D. (1992) · Annals of Neurology · doi:10.1002/ana.410320420 · Cited by 69 · see citing works
Self-citationThe structure and function of ferritin
Harrison, P. M. (1986) · Biochemical Education · doi:10.1016/0307-4412(86)90203-7 · Cited by 52 · see citing works
Free radicals and mitochondrial dysfunction in Parkinson's disease
Schapira, A. H. V., Hartley, A., Cleeter, M. W. J., et al. (1993) · Biochemical Society Transactions · doi:10.1042/bst0210367 · Cited by 37 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053 · see citing works
Self-citationThe role of iron in brain ageing and neurodegenerative disorders
Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R., & Zecca, L. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70117-6 · Cited by 1,819 · see citing works
Mitochondrial dynamics in health and disease: mechanisms and potential targets
Chen, W., Zhao, H., & Li, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01547-9 · Cited by 1,306 · see citing works
Oxidative stress and the pathogenesis of Parkinson's disease
Jenner, P., & Olanow, C. W. (1996) · Neurology · doi:10.1212/wnl.47.6_suppl_3.161s · Cited by 971 · see citing works
Self-citationMitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883 · see citing works
Self-citationMitochondrial dysfunction in Parkinson's disease
Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688 · see citing works
Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease
Zucca, F. A., Segura-Aguilar, J., Ferrari, E., Muñoz, P., Paris, I., Sulzer, D., Sarna, T., Casella, L., & Zecca, L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.012 · Cited by 659 · see citing works
Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo
Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620 · see citing works
Monzio Compagnoni, G., Di Fonzo, A., Corti, S., Comi, G. P., Bresolin, N., & Masliah, E. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01926-1 · Cited by 378 · see citing works
Iron Toxicity in Diseases of Aging: Alzheimer's Disease, Parkinson's Disease and Atherosclerosis
Altamura, S., & Muckenthaler, M. U. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1010 · Cited by 369 · see citing works
Lee, J.-M., Shih, A. Y., Murphy, T. H., & Johnson, J. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305204200 · Cited by 308 · see citing works
Surmeier, D. J., Guzman, J. N., Sanchez-Padilla, J., & Schumacker, P. T. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.045 · Cited by 236 · see citing works
Faucheux, B. A., Martin, M., Beaumont, C., Hauw, J., Agid, Y., & Hirsch, E. C. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01923.x · Cited by 229 · see citing works
Mitochondrial dysfunction in Parkinson's disease
Schapira, A. H. V. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402160 · Cited by 175 · see citing works
Self-citationDoes cellular iron dysregulation play a causative role in Parkinson’s disease?
Kaur, D., & Andersen, J. (2004) · Ageing Research Reviews · doi:10.1016/j.arr.2004.01.003 · Cited by 123 · see citing works
Faucheux, B. A., Martin, M., Beaumont, C., Hunot, S., Hauw, J., Agid, Y., & Hirsch, E. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01118.x · Cited by 116 · see citing works
Functional relevance of ceruloplasmin mutations in Parkinson's Disease
Hochstrasser, H., Tomiuk, J., Walter, U., Behnke, S., Spiegel, J., Krüger, R., Becker, G., Riess, O., & Berg, D. (2005) · The FASEB Journal · doi:10.1096/fj.04-3486fje · Cited by 87 · see citing works
Calcium, Bioenergetics, and Parkinson’s Disease
Zampese, E., & Surmeier, D. J. (2020) · Cells · doi:10.3390/cells9092045 · Cited by 79 · see citing works
Brain trace elements and aging
Hebbrecht, G., Maenhaut, W., & Reuck, J. D. (1999) · Nuclear Instruments and Methods in Physics Research Section B Beam Interactions with Materials and Atoms · doi:10.1016/s0168-583x(98)00938-0 · Cited by 53 · see citing works
Uranga, R. M., & Salvador, G. A. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/2850341 · Cited by 48 · see citing works
Quantitative study of mitochondrial complex I in platelets of parkinsonian patients
Blandini, F., Nappi, G., & Timothy Greenamyre, J. (1998) · Movement Disorders · doi:10.1002/mds.870130106 · Cited by 44 · see citing works
Kaur, D., Rajagopalan, S., Chinta, S., Kumar, J., Di Monte, D., Cherny, R. A., & Andersen, J. K. (2007) · Brain Research · doi:10.1016/j.brainres.2006.03.006 · Cited by 36 · see citing works
- Authors
- Mann, V. M., Cooper, J. M., Daniel, S. E., Srai, K., Jenner, P., Marsden, C. D., & Schapira, A. H. V.
- Affiliations
- The Royal Free Hospital (GB)
- King's College London (GB)
- Corresponding author
- Schapira, A. H. V.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1994-12
- Volume
- 36
- Issue
- 6
- Pages
- 876-881
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2090098521
- Cited by
- 251
- References
- 17
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 4 · 2023: 10 · 2022: 5 · 2021: 8 · 2020: 6 · 2019: 9 · 2018: 6 · 2017: 16 · 2016: 7 · 2015: 8 · 2014: 11 · 2013: 10 · 2012: 9
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Keywords
- Parkinson's disease, substantia nigra, complex I, iron, ferritin, oxidative damage, reactive iron, mitochondrial complex I deficiency
- MeSH terms
- Aged, Aged, 80 and over, Brain Chemistry, Ferritins, Humans, Iron, Parkinson Disease, Substantia Nigra, Zinc, NAD(P)H Dehydrogenase (Quinone)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review